Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study.
- Author:
Chen-Yi JIANG
1
;
Peng-Fei SHEN
2
;
Cheng WANG
3
;
Hao-Jun GUI
2
;
Yuan RUAN
1
;
Hao ZENG
2
;
Shu-Jie XIA
1
;
Qiang WEI
2
;
Fu-Jun ZHAO
1
Author Information
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords: Gleason score; biopsy; demography; propensity score; prostatic neoplasms
- MeSH: Adult; Age Factors; Aged; Aged, 80 and over; Biopsy/methods*; Humans; Logistic Models; Male; Middle Aged; Neoplasm Grading; Perineum; Propensity Score; Prostate/pathology*; Prostate-Specific Antigen/blood*; Prostatic Neoplasms/pathology*; Rectum
- From: Asian Journal of Andrology 2019;21(6):612-617
- CountryChina
- Language:English
- Abstract: This study compared the diagnostic efficacy of transrectal ultrasound (TRUS)-guided prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in patients with suspected prostate cancer (PCa). We enrolled 2962 men who underwent transrectal (n = 1216) or transperineal (n = 1746) systematic 12-core prostate biopsy. Clinical data including age, prostate-specific antigen (PSA) level, and prostate volume (PV) were recorded. To minimize confounding, we performed propensity score-matching analysis. We measured and compared PCa detection rates between TRBx and TPBx, which were stratified by clinical characteristics and Gleason scores. The effects of clinical characteristics on PCa detection rate were assessed by logistic regression. For all patients, TPBx detected a higher proportion of clinically significant PCa (P < 0.001). Logistic regression analyses illustrated that PV had a smaller impact on PCa detection rate of TPBx compared with TRBx. Propensity score-matching analysis showed that the detection rates in TRBx were higher than those in TPBx for patients aged >- 80 years (80.4% vs 56.5%, P = 0.004) and with PSA level 20.1-100.0 ng ml-1 (80.8% vs 69.1%, P = 0.040). In conclusion, TPBx was associated with a higher detection rate of clinically significant PCa than TRBx was; however, because of the high detection rate at certain ages and PSA levels, biopsy approaches should be optimized according to patents' clinical characteristics.